We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Illumina (ILMN) Stock Jumps on Q2 Earnings and Sales Beat
Read MoreHide Full Article
Illumina Inc. (ILMN - Free Report) just released its second quarter earnings results for fiscal 2016, posting earnings of $0.86 per share and revenue of $600 million
Currently, ILMN has a Zacks Rank #4 (Sell), but it is subject to change following the release of the company’s latest earnings report. Here are 5 key statistics from this just announced report below.
Illumina:
Beat earnings estimates. The company posted earnings of $0.86, topping our Zacks Consensus Estimate of $0.73. These numbers exclude $0.04 for nonrecurring items.
Beat revenue estimates. The company saw revenue figures of $600 million, topping our estimate of $594 million.
“We delivered solid second quarter financial results with notable strength across our sequencing consumable and array portfolios”-Francis deSouza, CEO and President of Illumina.
For this year, the company continues to forecast 12% revenues growth, and Illumina expects sales between $625 and $630 million in the third quarter.
ILMN was up $7.90, or 5.26%, to $158.0 as of 4:14 p.m. EST in after-hours trading shortly after its earnings report was released.
Here’s a graph that looks at Illumina’s quarterly revenues over the last five years.
Illumina Inc. is a leading developer of next-generation tools for the large-scale analysis of genetic variation and function. The company's tools will provide information that could be used to improve drugs and therapies, customize diagnoses and treatment, and cure disease. The company is developing a comprehensive line of products that can address the scale of experimentation and the breadth of functional analysis required to achieve the goals of molecular medicine.
Check back later for full coverage on Illumina’s second quarter earnings report!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Illumina (ILMN) Stock Jumps on Q2 Earnings and Sales Beat
Illumina Inc. (ILMN - Free Report) just released its second quarter earnings results for fiscal 2016, posting earnings of $0.86 per share and revenue of $600 million
Currently, ILMN has a Zacks Rank #4 (Sell), but it is subject to change following the release of the company’s latest earnings report. Here are 5 key statistics from this just announced report below.
Illumina:
Beat earnings estimates. The company posted earnings of $0.86, topping our Zacks Consensus Estimate of $0.73. These numbers exclude $0.04 for nonrecurring items.
Beat revenue estimates. The company saw revenue figures of $600 million, topping our estimate of $594 million.
“We delivered solid second quarter financial results with notable strength across our sequencing consumable and array portfolios”-Francis deSouza, CEO and President of Illumina.
For this year, the company continues to forecast 12% revenues growth, and Illumina expects sales between $625 and $630 million in the third quarter.
ILMN was up $7.90, or 5.26%, to $158.0 as of 4:14 p.m. EST in after-hours trading shortly after its earnings report was released.
Here’s a graph that looks at Illumina’s quarterly revenues over the last five years.
ILLUMINA INC Revenue (Quarterly)
ILLUMINA INC Revenue (Quarterly) | ILLUMINA INC Quote
Illumina Inc. is a leading developer of next-generation tools for the large-scale analysis of genetic variation and function. The company's tools will provide information that could be used to improve drugs and therapies, customize diagnoses and treatment, and cure disease. The company is developing a comprehensive line of products that can address the scale of experimentation and the breadth of functional analysis required to achieve the goals of molecular medicine.
Check back later for full coverage on Illumina’s second quarter earnings report!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>